Publicaciones en colaboración con investigadores/as de Liverpool Hospital (6)

2023

  1. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  2. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  3. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  2. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

2021

  1. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002